Domain Therapeutics Appoints Professor Michel Bouvier
News Sep 23, 2014
Domain Therapeutics has announced the nomination of Michel Bouvier as chairman of the company’s Scientific Advisory Board.
Michel Bouvier, PhD, is a professor in the Department of Biochemistry and Molecular Medicine at the University of Montreal and also chief executive officer of the Institute for Research in Immunology and Cancer (IRIC). In the coming months, he will work closely with Domain Therapeutics’ management team to assemble a group of academic and industrial peers.
“We are honored that an internationally renowned key opinion leader in GPCRs will advise on the technology and scientific evolution at our company”, said Pascal Neuville, board director and CEO of Domain Therapeutics. “His seminal contributions to our understanding of this major class of drug targets are invaluable and have led to paradigm shifts and the development of new classes of drugs. His remarkable skills in bridging basic research, drug discovery and medical needs will help Domain to reach its future goals and to maintain its leadership in the GPCR area.”
Michel Bouvier contributed to establishing the concept of ligand-biased signalling. He pioneered the use of bioluminescence resonance energy transfer (BRET)-based methods for the study of functional selectivity of GPCRs. These concepts are now integrated in Domain Therapeutics’ platform, BioSens-All™.
Professor Bouvier conducted post-doctoral training at Duke University under the direction of Robert Lefkowitz, winner of the 2012 Nobel Prize for Chemistry for his contribution in the GPCR field. Professor Bouvier was awarded the Hans-Selye/Bristol-Myers Squibb chair in Cell and Molecular Biology and the Merck-Frosst award from the Canadian Society of Biochemistry and Molecular & Cell Biology. He now holds the Canada Research Chair in Signal Transduction and Molecular Pharmacology. Professor Bouvier is a fellow of the Canadian Academy of Health Sciences and of the Royal Society of Canada.
“I look forward to helping guide the development of Domain Therapeutics’ research and development programs in the GPCR field”, said Professor Michel Bouvier. “The potential of the technologies assembled by Domain and the achievements made to date are great and constitute the groundwork for the company’s future success.”
A new type of opioid doesn’t have the side effects (such as increased pain sensitivity or and increased risk of chronic pain) associated with morphine and other opioid-based painkillers, and accelerates recovery time from pain compared to morphine, according to a new preclinical study.READ MORE